What is Polaryx Therapeutics, Inc. 's cash and cash equivalents, end of period?

Polaryx Therapeutics, Inc. (PLYX) reported cash and cash equivalents, end of period of 308000000.0% in Q1 2026.

What does cash and cash equivalents, end of period mean?

The total amount of cash and highly liquid assets held by the company, including funds that are legally restricted from immediate use.

Other

Cash and cash equivalents, end of period

Polaryx Therapeutics, Inc. Cash and cash equivalents, end of period decreased by 40.1% to 308000000.0% in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryLiquidity

SignalHigher is better

VolatilityVolatile

First reportedQ3 2022

Last reportedQ4 2025

How to read this metric

Higher levels indicate stronger liquidity and ability to meet short-term obligations, while lower levels may signal potential cash flow constraints.

Detailed definition

This encompasses highly liquid assets that are readily convertible to known amounts of cash, including cash on hand, ban...

Peer comparison

Standard across all industries; levels vary based on seasonal working capital needs and capital allocation strategies.

Metric ID: other_cash_cash_equivalents_restricted_cash_and_restrict_5675e1

Historical Data

4 periods

	Q4 '24	Q1 '25	Q4 '25	Q1 '26
Value	462,100,000%	416,200,000%	514,300,000%	308,000,000%
QoQ Change	—	-9.9%	+23.6%	-40.1%
YoY Change	—	—	+11.3%	-26.0%

Range308,000,000% – 514,300,000%

Avg YoY Growth-7.4%

Median YoY Growth-7.4%

Frequently Asked Questions

What is Polaryx Therapeutics, Inc. 's cash and cash equivalents, end of period?: Polaryx Therapeutics, Inc. (PLYX) reported cash and cash equivalents, end of period of 308000000.0% in Q1 2026.
What does cash and cash equivalents, end of period mean?: The total amount of cash and highly liquid assets held by the company, including funds that are legally restricted from immediate use.